Effects of daptomycin in combination with other antimicrobial agents: A review of in vitro and animal model studies

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 6, 2009, Pages 1130-1138

  Steenbergen, Judith N ^a   Mohr, John F ^a   Thorne, Grace M ^a  

^a CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Antimicrobials; Gentamicin; Rifampicin; Vancomycin

Indexed keywords

AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTRIAXONE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FOSFOMYCIN; FUSIDIC ACID; GENTAMICIN; HABEKACIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULTAMICILLIN; TEICOPLANIN; TIGECYCLINE; TIMENTIN; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

AGAR DIFFUSION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CLINICAL TRIAL; DEVICE INFECTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; EPSILOMETER TEST; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OSTEOMYELITIS; PHARMACODYNAMICS; REVIEW; SOFT TISSUE INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANIMAL; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DAPTOMYCIN; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GENTAMICINS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; RIFAMPIN;

EID: 76249093449     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp346     Document Type: Review

References (31)

1. Bonhoeffer S, Lipsitch M, Levin BR. Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA 1997; 94: 12106-11.
2. Mandell GL, Moorman DR. Treatment of experimental staphylococcal infections: effect of rifampin alone and in combination on development of rifampin resistance. Antimicrob Agents Chemother 1980; 17: 658-62.
3. Arbeit RD, Maki D, Tally FP et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673-81.
4. Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-65.
5. Chaudhary M, Shrivastava SM, Varughese L et al. Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients. Curr Clin Pharmacol 2008; 3: 118-22.
6. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med 1982; 97: 496-503.
7. Anastasiou DM, Thorne GM, Luperchio SA et al. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. Int J Antimicrob Agents 2006; 28: 385-8.
8. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 2538-44.
9. Hobbs JK, Miller K, O'Neill AJ et al. Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother 2008; 62: 1003-8.
10. Lorian V. Antibiotics in Laboratory Medicine. 5th edn. Philadelphia: Lippincott Williams & Wilkins, 2005.
11. Antimicrobial Agents and Chemotherapy: 2006 instructions to authors. Antimicrob Agents Chemother 2006; 50: 1-21.
12. Credito K, Lin G, Appelbaum PC. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Antimicrob Agents Chemother 2007; 51: 1504-7.
13. Snydman DR, McDermott LA, Jacobus NV. Evaluation of in vitro interaction of daptomycin with gentamicin or b-lactam antibiotics against Staphylococcus aureus and enterococci by FIC index and timed-kill curves. J Chemother 2005; 17: 614-21.
14. Silva M, Jacobus NV, Gorbach SL. In vitro activity of LY146032 against Gram-positive bacteria. Diagn Microbiol Infect Dis 1988; 9: 79-85.
15. Tsuji BT, Rybak MJ. Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin. Diagn Microbiol Infect Dis 2006; 54: 73-7.
16. Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004; 53: 530-2.
17. Pankey G, Ashcraft D, Patel N. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob Agents Chemother 2005; 49: 5166-8.
18. Cilli F, Aydemir S, Tunger A. In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci. J Chemother 2006; 18: 27-32.
19. Kuli B, de Barbeyrac B, Dauchy FA et al. In vitro activities of daptomycin, tigecycline, linezolid and eight other antibiotics, alone and in combination, against 41 Staphylococcus spp. clinical isolates from bone and joint infections. Int J Antimicrob Agents 2009; 33: 491-3.
20. Debbia E, Pesce A, Schito GC. In vitro activity of LY146032 alone and in combination with other antibiotics against Gram-positive bacteria. Antimicrob Agents Chemother 1988; 32: 279-81.
21. Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other b-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48: 2871-5.
22. Rand KH, Houck HJ, Silverman JA. Daptomycin-reversible rifampicin resistance in vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother. 2007; 59: 1017-20.
23. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48: 4665-72.
24. Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2005; 49: 2735-45.
25. Rose WE, Leonard SN, Rybak MJ. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008; 52: 3061-7.
26. Akins RL, Rybak MJ. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother 2000; 44: 1925-9.
27. Akins RL, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001; 45: 454-9.
28. Sakoulas G, Eliopoulos GM, Alder J et al. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 1714-8.
29. Miró JM, García-de-la-Mària C, Armero Y et al. The addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in the treatment of experimental endocarditis due to methicillinresistant Staphylococcus aureus. Antimicrob Agents Chemother 2009; doi:10.1128/AAC.00051-09.
30. John AK, Baldoni D, Haschke M et al. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother 2009; 53: 2719-24.
31. Lefebvre M, Jacqueline C, Amador G et al. Assessment of the in vivo activity of daptomycin (DAP) alone and in combination with rifampin (RA) against methicillin-resistant Staphylococcus aureus (MRSA) in a rabbit osteomyelitis model: comparison with vancomycin (VA). In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008. Abstract B-1013, p. 56. American Society for Microbiology, Washington, DC, USA.